GetTopicDetailResponse(id=88e9125169cb, topicName=吡羅西尼, introduction=, content=乳腺癌 吡羅西尼, image=null, comments=1, allHits=301, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sun Mar 16 22:19:43 CST 2025, time=2025-03-16, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=502569, tagList=[TagDto(tagId=502569, tagName=吡羅西尼)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2256448, encodeId=b0f32256448f8, content=<a href='/topic/show?id=88e9125169cb' target=_blank style='color:#2F92EE;'>#吡羅西尼#</a>（bireociclib，XZP-3287）是新一代高選擇性<a href='/topic/show?id=fc9744059a' target=_blank style='color:#2F92EE;'>#CDK4/6抑制劑#</a>，對(duì)CDK4的靶向選擇性更強(qiáng)。CDK4和CDK6共同參與細(xì)胞關(guān)鍵周期調(diào)節(jié)，也有研究提示，<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>等實(shí)體腫瘤的增殖通常主要依賴(lài)CDK4。
, objectTitle=多線治療失敗后，仍有42%患者臨床獲益！徐兵河教授領(lǐng)銜研究帶來(lái)乳腺癌潛在新選擇, objectType=article, longId=867488, objectId=631386e488bc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240522/1716375590097_5579292.png, objectUrl=/article/show_article.do?id=631386e488bc, replyNumber=0, likeNumber=39, createdTime=2025-03-17, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=631386e488bc, moduleTitle=多線治療失敗后，仍有42%患者臨床獲益！徐兵河教授領(lǐng)銜研究帶來(lái)乳腺癌潛在新選擇, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=631386e488bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2256376, encodeId=a7ab22563e6cd, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=88e9125169cb' target=_blank style='color:#2F92EE;'>#吡羅西尼#</a>, objectTitle=多線治療失敗后，仍有42%患者臨床獲益！徐兵河教授領(lǐng)銜研究帶來(lái)乳腺癌潛在新選擇, objectType=article, longId=867488, objectId=631386e488bc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240522/1716375590097_5579292.png, objectUrl=/article/show_article.do?id=631386e488bc, replyNumber=0, likeNumber=38, createdTime=2025-03-16, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=631386e488bc, moduleTitle=多線治療失敗后，仍有42%患者臨床獲益！徐兵河教授領(lǐng)銜研究帶來(lái)乳腺癌潛在新選擇, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=631386e488bc)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-03-16發(fā)表于陜西省
